The term "sleeve" appears in royalty financing documents in at least three distinct senses. They are not interchangeable. Each carries a different answer to the two questions that decide what a sleeve is worth: * Can a creditor of one sleeve reach the assets of another. * Has the cash

A royalty fund's pitch to a pharmaceutical finance function compresses three claims into a single sentence: monetisation is non-dilutive, it is off-credit, and it is good for the accounts. The first is almost always true. The second and third are true for one version of the

The week in numbers June 21 to 28, 2026: eight royalty-bearing license-outs, options, and collaborations (Antengene with K2 Therapeutics, Nuvectis with Haisco, Insilico with SK Biopharmaceuticals, Combotope with Boehringer Ingelheim, Abbisko with Lilly, Antares with Novartis, Ionis with Recordati, Elixirgen with Nippon Shinyaku), two signed acquisitions (AbbVie with

A mechanics walk-through of the royalty payment, from the shelf price to the wire and into the buyer's account, as of June 2026. A royalty deal is usually summarised in a single number. "Tiered double-digit on net sales." "Eight percent." "A

Hercules Capital. NYSE: HTGC. The largest non-bank venture lender in the United States, and as of June 2026 a royalty originator.

Aktis Oncology is a Boston radiopharmaceutical developer that did the opposite of last week's subject. Where Rallybio was hollowed into a shell and its one thin royalty ring-fenced into a contingent value right, Aktis spent 2024 and 2025 building a platform that big pharma paid to access,

A pharmaceutical royalty is a claim on protected sales. Strip away the science and the structuring and what a buyer is really pricing is a window: the years between launch and the day a generic or biosimilar can lawfully take the market. In the European Union, the instrument that sets

The rate quoted on a press release is a headline. What is actually paid is a function with arguments, and most of those arguments are drafted to move it. A royalty re-rates in two distinct places. The first is inside the underlying licence, where tiers, base adjustments, step-downs

The royalty economies in seeds, crop traits, fruit varieties, and bioprocessing platforms are just as real and just as patent-backed, with court records, license terms, and recent transactions to prove it, and almost no financing market on top.

The week in numbers June 14 to 20, 2026: one royalty-bearing license-out with a disclosed royalty rate (AbCellera with Jazz), two license or platform deals with undisclosed royalty terms (Protillion with Merck, cAMPfield with Newsoara), four re-rates of running third-party royalties (Karyopharm, F2G, Spero, Ligand), four